Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Known HIV infection with stable HIV therapy for ≥ 6 months~* Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\^3 for ≥ 6 months~* HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months~* Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study~* For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL~* Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L)~Exclusion Criteria:~* Taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction~* New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction (LVEF) \< 30%~* Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization~* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months~* Type 1 diabetes, new-onset or poorly controlled type 2 diabetes~* Uncontrolled hypertension~* Taken a cholesteryl ester transfer protein inhibitor in the last 12 months~* Moderate to severe renal dysfunction~* Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of at least 1 year duration prior to randomization is allowed)~* Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization~Other exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM (Type: EXPERIMENTAL): Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
- Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM (Type: PLACEBO_COMPARATOR): Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).